{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:33:52Z","timestamp":1793046832803,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacbts.2026.101698","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:50:35Z","timestamp":1789768235000},"page":"101698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin Prevents Heart Failure With Preserved Ejection Fraction by Inhibiting the Sodium\/Hydrogen Exchanger"],"prefix":"10.1016","volume":"11","author":[{"given":"Man","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeoung-Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell C.","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruthvika","family":"Murikinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5843-5961","authenticated-orcid":false,"suffix":"Jr.","given":"Samuel C.","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2026.101698_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure Society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacbts.2026.101698_bib2","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101698_bib3","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1161\/CIRCULATIONAHA.110.954388","article-title":"Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum","volume":"123","author":"Borlaug","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101698_bib4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.mcna.2012.07.001","article-title":"Pathophysiology of systolic and diastolic heart failure","volume":"96","author":"Chatterjee","year":"2012","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jacbts.2026.101698_bib5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14779072.2018.1497485","article-title":"Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction","volume":"16","author":"Plitt","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacbts.2026.101698_bib6","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.111.066423","article-title":"Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction","volume":"125","author":"Aljaroudi","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101698_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2011.1201","article-title":"Progression of left ventricular diastolic dysfunction and risk of heart failure","volume":"306","author":"Kane","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacbts.2026.101698_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40292-013-0031-2","article-title":"Progression of left ventricular diastolic dysfunction in ethnic minorities","volume":"21","author":"Prendergast","year":"2014","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.jacbts.2026.101698_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2026.101698_bib11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib15","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1161\/CIRCULATIONAHA.107.188965","volume":"117","author":"Schocken","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101698_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ncpcardio1245","article-title":"Diastolic heart failure: mechanisms and controversies","volume":"5","author":"Ouzounian","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib17","doi-asserted-by":"crossref","first-page":"8265","DOI":"10.1038\/s41598-025-93144-9","article-title":"Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure","volume":"15","author":"Mourad","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacbts.2026.101698_bib18","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00424-017-2056-1","article-title":"Expression profiling and immunolocalization of Na(+)-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats","volume":"469","author":"Maduni\u0107","year":"2017","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jacbts.2026.101698_bib19","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jacc.2025.08.005","article-title":"Beyond adiposity: embracing complexity in diabetes-associated HFpEF","volume":"86","author":"Krumholz","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jmcb\/mjac028","article-title":"Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics","volume":"14","author":"Abudureyimu","year":"2022","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.jacbts.2026.101698_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123182","article-title":"Magnesium supplementation improves diabetic mitochondrial and cardiac diastolic function","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacbts.2026.101698_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020205","article-title":"Magnesium deficiency causes a reversible, metabolic, diastolic cardiomyopathy","volume":"10","author":"Liu","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacbts.2026.101698_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017069","article-title":"Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction","volume":"98","author":"Nishihara","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacbts.2026.101698_bib24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jacbts.2022.08.003","article-title":"Inflammatory macrophage interleukin-1\u03b2 mediates high fat diet induced heart failure with preserved ejection fraction","volume":"8","author":"Liu","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacbts.2026.101698_bib25","article-title":"TRPM7 kinase controls cardiac inflammation in a model of heart failure with preserved ejection fraction","volume":"125","author":"Liu","year":"2026","journal-title":"Biophysical J"},{"key":"10.1016\/j.jacbts.2026.101698_bib26","doi-asserted-by":"crossref","first-page":"H1103","DOI":"10.1152\/ajpheart.00903.2007","article-title":"Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension","volume":"294","author":"Touyz","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/HYPERTENSIONAHA.120.14909","article-title":"Magnesium supplementation attenuates pulmonary hypertension via regulation of magnesium transporters","volume":"77","author":"Wang","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2026.101698_bib28","article-title":"Cardiac TRPM7 causes diabetic heart failure with preserved ejection fraction","volume":"10","author":"Liu","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacbts.2026.101698_bib29","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1074\/jbc.M308820200","article-title":"Characterization of the protein kinase activity of TRPM7\/ChaK1, a protein kinase fused to the transient receptor potential ion channel","volume":"279","author":"Ryazanova","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacbts.2026.101698_bib30","doi-asserted-by":"crossref","first-page":"7599","DOI":"10.1038\/srep07599","article-title":"Elucidating the role of the TRPM7 alpha-kinase: TRPM7 kinase inactivation leads to magnesium deprivation resistance phenotype in mice","volume":"4","author":"Ryazanova","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacbts.2026.101698_bib31","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1113\/JP274006","article-title":"The TRPM7 channel kinase regulates store-operated calcium entry","volume":"595","author":"Faouzi","year":"2017","journal-title":"J Physiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000327958","article-title":"Alteration of the transcriptional profile of human embryonic kidney cells by transient overexpression of mouse TRPM7 channels","volume":"27","author":"Lee","year":"2011","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jacbts.2026.101698_bib33","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2014.03.046","article-title":"The TRPM7 chanzyme is cleaved to release a chromatin-modifying kinase","volume":"157","author":"Krapivinsky","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jacbts.2026.101698_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2013.01.031","article-title":"TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway","volume":"333","author":"Meng","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jacbts.2026.101698_bib35","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41467-021-23005-2","article-title":"TRPM7 kinase-mediated immunomodulation in macrophage plays a central role in magnesium ion-induced bone regeneration","volume":"12","author":"Qiao","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacbts.2026.101698_bib36","doi-asserted-by":"crossref","first-page":"E3037","DOI":"10.1073\/pnas.1311865110","article-title":"Ion channel-kinase TRPM7 is required for maintaining cardiac automaticity","volume":"110","author":"Sah","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jacbts.2026.101698_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCULATIONAHA.112.000768","article-title":"Timing of myocardial trpm7 deletion during cardiogenesis variably disrupts adult ventricular function, conduction, and repolarization","volume":"128","author":"Sah","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101698_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.34067\/KID.0006672021","article-title":"Comparative effects of sodium-glucose cotransporter 2 inhibitors on serum electrolyte levels in patients with type 2 diabetes: a pairwise and network meta-analysis of randomized controlled trials","volume":"3","author":"Zhang","year":"2022","journal-title":"Kidney360"},{"key":"10.1016\/j.jacbts.2026.101698_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100697","article-title":"SGLT2 inhibitors in management of severe hypomagnesemia in patients without diabetes: a report of 4 cases","volume":"5","author":"Shah","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib40","article-title":"Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function","volume":"2022","author":"Wang","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jacbts.2026.101698_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.freeradbiomed.2024.01.015","article-title":"Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress","volume":"213","author":"Luna-Marco","year":"2024","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.31264","article-title":"Empagliflozin, a sodium-glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome","volume":"239","author":"Li","year":"2024","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","article-title":"A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats","volume":"17","author":"Durak","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacbts.2026.101698_bib44","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacbts.2026.101698_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2026.101698_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00223-001-1091-1","article-title":"Magnesium deficiency: effect on bone and mineral metabolism in the mouse","volume":"72","author":"Rude","year":"2003","journal-title":"Calcified Tissue Int"},{"key":"10.1016\/j.jacbts.2026.101698_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6305735","article-title":"The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-\/-) mice","volume":"2016","author":"Leng","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jacbts.2026.101698_bib48","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154324","article-title":"Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice","volume":"111","author":"Wei","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.jacbts.2026.101698_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247234","article-title":"Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells","volume":"16","author":"Zaibi","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2026.101698_bib51","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1161\/01.CIR.0000093277.20968.C7","article-title":"Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway","volume":"108","author":"Teshima","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101698_bib52","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.3390\/ijms23073910","article-title":"Rosmarinic acid, as an NHE1 activator, decreases skin surface pH and improves the skin barrier function","volume":"23","author":"Jung","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacbts.2026.101698_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yjmcc.2012.10.011","article-title":"Mitochondrial dysfunction causing cardiac sodium channel downregulation in cardiomyopathy","volume":"54","author":"Liu","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib54","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025295","article-title":"Circulating S-glutathionylated cMyBP-C as a biomarker for cardiac diastolic dysfunction","volume":"11","author":"Zhou","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacbts.2026.101698_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003046","article-title":"Role of mitochondrial oxidative stress in glucose tolerance, insulin resistance, and cardiac diastolic dysfunction","volume":"5","author":"Jeong","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacbts.2026.101698_bib56","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1038\/s41598-023-34789-2","article-title":"TRPM7 kinase mediates hypomagnesemia-induced seizure-related death","volume":"13","author":"Liu","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacbts.2026.101698_bib57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41590-018-0272-2","article-title":"Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction","volume":"20","author":"Dick","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jacbts.2026.101698_bib58","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-020-0686-5","article-title":"Publisher correction: blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly","volume":"21","author":"De Maeyer","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jacbts.2026.101698_bib59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.vascn.2014.11.005","article-title":"Human fetal ventricular cardiomyocyte, RL-14 cell line, is a promising model to study drug metabolizing enzymes and their associated arachidonic acid metabolites","volume":"71","author":"Maayah","year":"2015","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.jacbts.2026.101698_bib60","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacbts.2026.101698_bib61","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin attenuates Na(+)\/H(+) Exchanger-1 in cardiofibroblasts via AMPK activation","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacbts.2026.101698_bib62","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","article-title":"Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts","volume":"115","author":"Uthman","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2026.101698_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacbts.2026.101698_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312677","article-title":"Crosstalk between sodium-glucose cotransporter inhibitors and sodium-hydrogen exchanger 1 and 3 in cardiometabolic diseases","volume":"22","author":"Al-Shamasi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacbts.2026.101698_bib65","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/cvr\/cvae156","article-title":"Crucial role for sensory nerves and Na\/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation","volume":"120","author":"Forrester","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2026.101698_bib66","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.bbagen.2017.01.034","article-title":"Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion","volume":"1861","author":"Song","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.jacbts.2026.101698_bib67","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1002\/jcp.29820","article-title":"Suppression of TRPM7 enhances TRAIL-induced apoptosis in triple-negative breast cancer cells","volume":"235","author":"Song","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib68","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.31083\/j.rcm.2018.02.021","article-title":"Inhibition of the sodium-proton antiporter (exchanger) is a plausible mechanism of potential benefit and harm for drugs designed to block sodium glucose co-transporter 2","volume":"19","author":"McCullough","year":"2018","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib70","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s10741-022-10220-2","article-title":"Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?","volume":"27","author":"Wichaiyo","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacbts.2026.101698_bib71","article-title":"Serum magnesium, outcomes, and the effect of empagliflozin in heart failure with mildly reduced and preserved ejection fraction: findings from EMPEROR-preserved","volume":"14","author":"Ferreira","year":"2026","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacbts.2026.101698_bib72","article-title":"Serum magnesium and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-reduced","volume":"14","author":"Ferreira","year":"2026","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacbts.2026.101698_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2019.06.007","article-title":"Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials","volume":"33","author":"Toto","year":"2019","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jacbts.2026.101698_bib74","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.HYP.34.3.442","article-title":"Activation of the Na(+)-H+ exchanger modulates angiotensin II-stimulated Na(+)-dependent Mg2+ transport in vascular smooth muscle cells in genetic hypertension","volume":"34","author":"Touyz","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2026.101698_bib75","doi-asserted-by":"crossref","first-page":"C1024","DOI":"10.1152\/ajpcell.1992.262.4.C1024","article-title":"Intracellular pH modulates cytosolic free magnesium in cultured chicken heart cells","volume":"262","author":"Freudenrich","year":"1992","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib76","doi-asserted-by":"crossref","first-page":"12779","DOI":"10.1093\/nar\/gku951","article-title":"Identification of a Mg2+-sensitive ORF in the 5'-leader of TRPM7 magnesium channel mRNA","volume":"42","author":"Nikonorova","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jacbts.2026.101698_bib77","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jacbts.2026.101698_bib78","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101698_bib79","article-title":"Dapagliflozin protects methamphetamine-induced cardiomyopathy by alleviating mitochondrial damage and reducing cardiac function decline in a mouse model","volume":"13","author":"He","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacbts.2026.101698_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101620","article-title":"Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism","volume":"66","author":"Op den Kamp","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.jacbts.2026.101698_bib81","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011107","article-title":"Empagliflozin improves diastolic function in HFpEF by restabilizing the mitochondrial respiratory chain","volume":"17","author":"Schauer","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2026.101698_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102288","article-title":"Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway","volume":"52","author":"Cai","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.jacbts.2026.101698_bib83","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2026.101698_bib84","article-title":"Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways","volume":"10","author":"Hasan","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacbts.2026.101698_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1011669","article-title":"Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy","volume":"13","author":"Du","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacbts.2026.101698_bib86","article-title":"Canagliflozin prevents lipid accumulation, mitochondrial dysfunction, and Gut microbiota dysbiosis in mice with diabetic cardiovascular disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacbts.2026.101698_bib87","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib88","doi-asserted-by":"crossref","first-page":"22373","DOI":"10.1074\/jbc.272.36.22373","article-title":"Na+\/H+ exchangers of mammalian cells","volume":"272","author":"Orlowski","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacbts.2026.101698_bib89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ceca.2004.06.006","article-title":"Inhibition of the Na+-H+ exchanger with cariporide abolishes stretch-induced calcium but not sodium accumulation in mouse ventricular myocytes","volume":"37","author":"Kondratev","year":"2005","journal-title":"Cell Calcium"},{"issue":"suppl 1","key":"10.1016\/j.jacbts.2026.101698_bib90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1540-8191.18.s1.4.x","article-title":"The role of sodium-hydrogen ion exchange in patients undergoing coronary artery bypass grafting","volume":"18","author":"Bolli","year":"2003","journal-title":"J Card Surg"},{"key":"10.1016\/j.jacbts.2026.101698_bib91","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0735-1097(01)01608-4","article-title":"The Na(+)\/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial","volume":"38","author":"Zeymer","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2026.101698_bib92","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","article-title":"Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute","volume":"119","author":"Lee","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101698_bib93","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018574","article-title":"Sex differences in heart failure with preserved ejection fraction","volume":"10","author":"Sotomi","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X26002214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X26002214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:36:35Z","timestamp":1793043395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X26002214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2452302X26002214"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2026.101698","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin Prevents Heart Failure With Preserved Ejection Fraction by Inhibiting the Sodium\/Hydrogen Exchanger","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2026.101698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101698"}}